New insights about young-onset CRC tumour-related bacteria could lead to new diagnostic markers and therapeutic targets.
List view / Grid view
Lactate producing bacteria is responsible for rewiring metabolic signalling pathways, causing resistance to radiation therapy.
US investigators find that some cases of Lynch syndrome, the most common hereditary cancer condition, are missed in younger patients under current screening guidelines.
In this interview with Drug Target Review’s Izzy Wood and Dr Isaac Klein, Chief Scientific Officer at Dewpoint Therapeutics, discuss the innovative potential of condensate biology in revolutionising drug discovery. By targeting disease-driving condensates, Dewpoint’s research pushes boundaries by offering new hope for tackling diseases like ALS and colorectal cancer.
US researchers found that the severity of muscle wasting from cancer is related to the type, size and location of the tumour, in mice.
US researchers find that bacteria could help tumours progress and resist treatment.
Researchers have found that blocking key enzymes could boost anti-cancer T cell responses and resistance to immunosuppression.
According to a new study, a metabolic enzyme studied in cancer biology is key for T-cell function, offering a novel target for anti-inflammatory therapeutics. Dr Jeffrey Rathmell and Ayaka Sugiura from Vanderbilt University in the US discuss their study with Drug Target Review and why inhibiting or genetically deleting the…
Boosting dendritic cells prevented immunotherapy resistance in mouse models, suggesting a new approach to colorectal cancer therapies.
RGX-202 was found to foil a key pathway that cancer cells rely on for energy in mice, presenting a possible new colorectal cancer therapy.
A nanotherapeutic delivery system displayed high efficacy against metastatic tumours in mice, potentially improving chemotherapy treatments.
Researchers created their new method to analyse chromosomes in 3D, revealing how misconfigurations play a role in cancer.
Having synthesised the curcusone D compound, researchers demonstrated its promise as the first BRAT1 inhibitor, making it a potential cancer therapy.
Researchers have found that colorectal cancer-associated fibroblasts can be altered using a gremlin 1-neutralising antibody or by overexpressing meflin.